Nöromusküler Bloker İlaçlar
Özet
Nöromusküler bloker (NMB) ilaçlar, kas sinir kavşağındaki iletimi bloke ederek iskelet kaslarını paralize eden ve yoğun bakım ünitelerinde entübasyon, ventilatör uyumu, oksijenasyonu iyileştirme gibi amaçlarla kullanılan kritik ajanlardır. Etki mekanizmalarına göre depolarizan (süksinilkolin) ve nondepolarizan (benzilizokinolin ve aminosteroid türevleri) olarak ikiye ayrılırlar. Süksinilkolin en hızlı etki başlangıcına sahip tek depolarizan ajandır ancak kritik hastalarda hiperkalemi ve kardiyak arrest riskine yol açabilir. Nondepolarizan ajanlardan atrakuryum ve sisatrakuryum, organ fonksiyonlarından bağımsız Hoffman eliminasyonu ile yıkıldıklarından böbrek ve karaciğer yetmezliği olan hastalarda güvenle tercih edilir. Aminosteroid yapılı rokuronyum, süksinilkoline hızlı bir alternatif sunarken; veküronyum ve panküronyum organ yetmezliklerinde birikim yapabilir. Tedavi sürecinde hastaların TOF veya periferik sinir stimülasyonu ile izlenmesi, uzamış paralizi ve kas güçsüzlüğü gibi ciddi yan etkileri önlemede önemlidir. Bloğun geri çevrilmesinde ise neostigmin ve edrofonyum gibi antikolinesterazlar ile steroid yapılı kas gevşeticileri kapsülleyerek inaktive eden sugamadeks kullanılır. Sonuç olarak, yoğun bakımda NMB ilaç kullanımı kararı, hastanın komorbiditelerine göre bireyselleştirilmeli, mutlaka eş zamanlı derin sedasyon ve analjezi sağlanarak klinik yanıtlar yakından izlenmelidir.
Neuromuscular blocking (NMB) agents are critical drugs that paralyze skeletal muscles by blocking nerve transmission at the neuromuscular junction, utilized in intensive care units for purposes such as intubation, ventilator synchrony, and improving oxygenation. They are categorized into depolarizing (succinylcholine) and nondepolarizing (benzylisoquinoline and aminosteroid derivatives) agents based on their mechanisms of action. Succinylcholine is the only depolarizing agent with the fastest onset of action, but it carries risks of hyperkalemia and cardiac arrest in critically ill patients. Among nondepolarizing agents, atracurium and cisatracurium are safely preferred in patients with renal and hepatic failure because they are metabolized via organ-independent Hoffman elimination. Aminosteroid-structured rocuronium provides a rapid alternative to succinylcholine, whereas vecuronium and pancuronium may accumulate in patients with organ dysfunction. Monitoring patients with TOF or peripheral nerve stimulation during treatment is essential to prevent severe adverse effects like prolonged paralysis and muscle weakness. Reversal of the blockade is achieved using anticholinesterases, such as neostigmine and edrophonium, or sugammadex, which inactivates steroidal muscle relaxants by encapsulation. Ultimately, the decision to use NMB agents in the intensive care unit must be individualized based on the patient's comorbidities, and clinical responses must be closely monitored under mandatory concurrent deep sedation and analgesia.
Referanslar
Tezcan B, Turan S, Özgök A. Current Use of Neuromuscular Blocking Agents in Intensive Care Units. Turk J Anaesthesiol Reanim. 2019, 47(4):273-281. doi: 10.5152/TJAR.2019.33269.
Murray MJ, DeBlock H, Erstad B, et al., Clinical Practice Guidelines for Sustained Neuromuscular Blockade in the Adult Critically Ill Patient. Crit Care Med. 2016, 44(11):2079-2103. doi: 10.1097/CCM.0000000000002027.
Miller, R. D., Eriksson, L. I., Fleisher, L. A., Wiener-Kronish, J. P., Cohen, N. H., & Young, W. L. (2014). Miller's anesthesia e-book. Elsevier Health Sciences.
Basta SJ. Clinical pharmacology of mivacurium chloride: a review. J Clin Anesth. 1992, 4(2):153-63. doi: 10.1016/0952-8180(92)90034-x.
deBacker J, Hart N, Fan E. Neuromuscular Blockade in the 21st Century Management of the Critically Ill Patient. Chest. 2017, 151(3):697-706. doi: 10.1016/j.chest.2016.10.040.
Greenberg SB, Vender J. The use of neuromuscular blocking agents in the ICU: where are we now? Crit Care Med. 2013, 41(5):1332-44. doi: 10.1097/CCM.0b013e31828ce07c.
Aronoff, G. R. (2007). Drug prescribing in renal failure. ACP Press.
Polderman KH, Herold I. Therapeutic hypothermia and controlled normothermia in the intensive care unit: practical considerations, side effects, and cooling methods. Crit Care Med. 2009, 37(3):1101-20. doi: 10.1097/CCM.0b013e3181962ad5.
Murray MJ, Cowen J, DeBlock H, et al., Task Force of the American College of Critical Care Medicine (ACCM) of the Society of Critical Care Medicine (SCCM), American Society of Health-System Pharmacists, American College of Chest Physicians. Clinical practice guidelines for sustained neuromuscular blockade in the adult critically ill patient. Crit Care Med. 2002, 30(1):142-56. doi: 10.1097/00003246-200201000-00021.
Gill KV, Voils SA, Chenault GA, et al., Perceived versus actual sedation practices in adult intensive care unit patients receiving mechanical ventilation. Ann Pharmacother. 2012, 46(10):1331-9. doi: 10.1345/aph.1R037.
Vaja, R., McNicol, L., & Sisley, I. (2010). Anaesthesia for patients with liver disease. Continuing Education in Anaesthesia, Critical Care & Pain, 10(1), 15-19.
Craig RG, Hunter JM. Neuromuscular blocking drugs and their antagonists in patients with organ disease. Anaesthesia. 2009, 64 Suppl 1:55-65. doi: 10.1111/j.1365-2044.2008.05871.x.
Bittner EA, Shank E, Woodson L, et al., Acute and perioperative care of the burn-injured patient. Anesthesiology. 2015, 122(2):448-64. doi: 10.1097/ALN.0000000000000559.
Rudis MI, Sikora CA, Angus E, et al., A prospective, randomized, controlled evaluation of peripheral nerve stimulation versus standard clinical dosing of neuromuscular blocking agents in critically ill patients. Crit Care Med. 1997, 25(4):575-83. doi: 10.1097/00003246-199704000-00005.
Kleinpell R, Bedrosian C, McCormick L, et al., Use of peripheral nerve stimulators to monitor patients with neuromuscular blockade in the ICU. Am J Crit Care. 1996, 5(6):449-54.
Raps EC, Bird SJ, Hansen-Flaschen J. Prolonged muscle weakness after neuromuscular blockade in the intensive care unit. Crit Care Clin. 1994, 10(4):799-813.
Tasaka CL, Duby JJ, Pandya K, et al., Inadequate Sedation During Therapeutic Paralysis: Use of Bispectral Index in Critically Ill Patients. Drugs Real World Outcomes. 2016, 28;3(2):201-208. doi: 10.1007/s40801-016-0076-3.
Debaene B, Plaud B, Dilly MP, et al., Residual paralysis in the PACU after a single intubating dose of nondepolarizing muscle relaxant with an intermediate duration of action. Anesthesiology. 2003, 98(5):1042-8. doi: 10.1097/00000542-200305000-00004.
Bom A, Bradley M, Cameron K, et al., A novel concept of reversing neuromuscular block: chemical encapsulation of rocuronium bromide by a cyclodextrin-based synthetic host. Angew Chem Int Ed Engl. 2002, 18;41(2):266-70. doi: 10.1002/1521-3773(20020118)41:2<265::aid-anie265>3.0.co;2-q.
